sameAs
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineageMolecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locusMesoangioblast stem cells ameliorate muscle function in dystrophic dogsThe oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophilsCorrection of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells.Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide geneA Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease.Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family.Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.A family of rapidly evolving genes from the sex reversal critical region in Xp21.Therapeutic applications for hematopoietic stem cell gene transfer.Suicide-gene-Transduced donor T-cells for controlled graft-versus-host disease and graft-versus-tumor.Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response.Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice.Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells.Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.De novo design of a tumor-penetrating peptide.The suicide gene therapy challenge: how to improve a successful gene therapy approach.NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors.Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation.Progress and prospects: graft-versus-host disease.Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.Twenty-five years of gene therapy for genetic diseases and leukemia: The road to marketing authorization of the first ex vivo gene therapies.2D TR-NOESY experiments interrogate and rank ligand-receptor interactions in living human cancer cells.Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses.Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin.Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts.The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies.Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).Expression and purification of a human, soluble Arylsulfatase A for Metachromatic Leukodystrophy enzyme replacement therapy.Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence.
P50
Q24646800-2071668B-C549-471A-9193-27CD7DAA73F9Q28138853-E6449C47-CCF0-4BC2-836C-1CF30266DD97Q28274324-B9C7A049-8230-40CD-8571-C34EDAA2A384Q28387803-180E8244-1BB2-499F-8BCD-7345E4CE0BEBQ30501325-BA3FB765-BF83-4DC2-B2CD-2BD43233FF65Q30537403-35C010AF-FAD8-4CCC-BCEA-DED4A1FD7052Q32061758-B7E4C585-DE7E-4B2D-916E-3C4FAC8BDE44Q33864463-21A97BF9-29AA-4067-BA22-803C77BC2C13Q34163587-D5897E38-F7D6-4705-AE56-089F1777D37EQ34356914-29F4D971-A016-4FA0-9AD0-E9EA46EF2ACFQ34368927-B878FF03-E28E-42D2-BC60-12DD3AA71FC6Q34580287-9A2A527A-9452-46D9-8B32-3F7898EB30AEQ35015535-18D9ACCF-B316-4E66-8126-8CD276A4A522Q35050844-55A814A2-5831-4AEB-98FF-F3C12315EF0FQ35112505-A846C0D2-8920-4531-B63A-3A1F92A856B3Q35916190-C97990E9-96B3-4DB0-AE63-703A971E159CQ35941149-E6FCBAA9-AC00-45F1-BE67-DE1BEF62471FQ36528787-8680D64E-A332-40F2-94AE-51A8857FE763Q36544864-B027EB7B-B94B-4707-9D5E-4ADDE65D3FB2Q36823693-48AFE922-124D-40C0-B8EB-034D0C8F27A7Q37043370-E9BC8972-EB3A-46FF-8A7E-C2030D927959Q37570436-B07092B2-02FA-4B5D-B157-AD326F60FDC8Q37685142-4971093E-6631-4A64-A3A1-14956D0BB4E5Q37761297-54A46BC1-13FC-4C7A-973E-6FA645BF35EEQ38710443-E880C5F1-5E59-441C-AE2B-0FE8351BF42AQ38855371-68F0A9E3-7B78-4953-8D7E-DB2A0C33EBB8Q39098372-DCC2B5BA-5F1F-4E87-AC0A-A0BDABD013B8Q39139624-740F444A-56F2-46DA-8564-D298ABFA013EQ39445822-AC0A3099-28B3-4CFF-90D7-41437ACD040BQ39754484-FCFC07B0-44BC-44FA-B7EB-BB192C8070C9Q39758426-B78B008C-03A9-4299-880F-2E3F6ED00455Q39906204-26F8F3D2-E160-4DDD-8D8E-4C6FCCE1D037Q39982466-F71AF624-5EB2-41F8-9D76-D0491CB206F2Q40077786-C35064E2-C4CF-4611-B937-4BB8CB0F13F9Q40162750-3C188BFE-C8D8-4738-81C4-BAADA66B1ACBQ40165690-EE2C7E13-820A-4F9A-ADB3-83E0006B3772Q40307991-14C094AE-B23E-4DA0-9E49-C9601154481EQ40366565-768AE6BF-2B80-4558-9F33-284FCFD2B097Q40429108-01D05B8F-F52C-4A93-9812-D632AACB8EBFQ40662338-DF166F25-A6EF-4DB7-8068-A718F714A1C0
P50
description
Italiaans bioloog
@nl
Italian inventor
@en
ahli biologi asal Italia
@id
biologo e genetista italiano
@it
ceapadóir Iodálach
@ga
italienischer Biologe und Genetiker
@de
name
Claudio Bordignon
@ace
Claudio Bordignon
@ast
Claudio Bordignon
@ca
Claudio Bordignon
@da
Claudio Bordignon
@de
Claudio Bordignon
@en
Claudio Bordignon
@es
Claudio Bordignon
@fr
Claudio Bordignon
@ga
Claudio Bordignon
@id
type
label
Claudio Bordignon
@ace
Claudio Bordignon
@ast
Claudio Bordignon
@ca
Claudio Bordignon
@da
Claudio Bordignon
@de
Claudio Bordignon
@en
Claudio Bordignon
@es
Claudio Bordignon
@fr
Claudio Bordignon
@ga
Claudio Bordignon
@id
prefLabel
Claudio Bordignon
@ace
Claudio Bordignon
@ast
Claudio Bordignon
@ca
Claudio Bordignon
@da
Claudio Bordignon
@de
Claudio Bordignon
@en
Claudio Bordignon
@es
Claudio Bordignon
@fr
Claudio Bordignon
@ga
Claudio Bordignon
@id
P106
P21
P27
P31
P569
1950-07-06T00:00:00Z